Safety Reporting Systems Will Be Focus Of IoM Medication Errors Cmte. April 14
This article was originally published in The Pink Sheet Daily
Committee on Identifying and Preventing Medication Errors panel discussion topics for the April 13-15 meeting also include systems design, technology, quality, patient-consumer initiatives and federal and state legislative policy.
You may also be interested in...
The Institute of Medicine Committee on Drug Safety should provide cost savings estimates in its recommendations on medication errors, the Centers for Medicare & Medicaid Services said
The agency is in discussions with the Institute of Medicine to initiate a study on the effectiveness of the drug safety system, particularly in the post-marketing phase. The IoM study is the centerpiece of an FDA drug safety initiative, announced Nov. 5, that packages together ongoing projects.
Ag/FDA subcommittee had tabled FDA hearing pending confirmation of a permanent agency commissioner. House cleared FDA 2006 spending in early June.